Treatment of Subacute Cutaneous Lupus Erythematosus with Severe or Widespread Skin Lesions

This protocol covers subacute cutaneous lupus erythematosus (SCLE) in patients who present with severe or widespread skin lesions, who are at risk of scarring, or who face risk of developing systemic disease — a distinct clinical situation that calls for a structured systemic treatment approach.

Clinical scenario

The target population includes patients with severe or widespread active cutaneous lupus lesions, and particularly those at elevated risk for scarring or for progression to systemic lupus erythematosus. Antimalarials are recommended as the foundation of long-term systemic treatment in this group. In patients with severe or widespread active lesions, systemic corticosteroids are recommended as an initial addition alongside antimalarials.

Treatment approach — partial overview

For patients whose disease requires further systemic control, an immunosuppressant — MMF is one agent used in this context — may be added to the regimen, preferably in combination with antimalarials. The complete protocol specifies which patients qualify, the full sequencing, alternative agents, and dosing strategy.

Instant Access to Structured Evidence-Based Regimens

References

We recommend antimalarials as first-line and long-term systemic treatment in all CLE patients with severe or widespread skin lesions, in particular in patients with the risk of scarring and development of systemic disease.
In severe or widespread active CLE lesions, systemic corticosteroids are recommended as first-line treatment in addition to antimalarials.
We recommend MMF as third-line treatment in refractory CLE patients, preferably in addition to antimalarials.
We recommend 2 x 500 mg MMF per day as starting dose that can be increased up to 3 g per day depending on the clinical response.
We suggest MPA as an alternative treatment to MMF.

View source ↗